Shifting the Trajectory: Early Intervention Strategies in SLE

Grand Horizon Ballroom C, Marriott Marquis Chicago | Developed and offered by GSK

---

Program Description

Join this live symposium to discuss early biologic therapy for systemic lupus erythematosus (SLE), focusing on disease modification and guideline-based care to improve patient outcomes.

Facilitated by Drs. Maria Dall’Era and Ashira Blazer, this symposium will equip clinicians to identify key clinical characteristics that support early intervention with advanced therapies and apply a disease modification framework as a proactive strategy to slow the progression of organ damage and improve patient outcomes.

Organ damage can occur in approximately 30–50% of patients with SLE within 5 years of diagnosis and can significantly increase their mortality risk.^1-4 Prompt initiation of effective treatment to prevent flares and organ damage, as emphasized in the 2023 EULAR SLE recommendations, is a key goal of management.⁵ The 2025 ACR SLE guidelines further highlight optimal disease control, achieving remission or low disease activity, as essential for improving long-term clinical outcomes.⁶

The disease modification framework provides a structured approach for selecting therapies aimed at reducing disease activity and potential organ damage accrual.⁷ Clinicians will explore practical applications of the disease modification framework and gain insights into identifying patients who may benefit from early biologic therapy. Interactive patient case studies and audience discussions will be facilitated by Drs. Dall’Era and Blazer.

This program is developed and offered by GSK. This is not an official program of the American College of Rheumatology.

References

1. Urowitz MB, et al. Arthritis Care Res (Hoboken). 2012;64:132–7.
2. Stirnadel-Farrant HA, et al. Rheumatol Ther. 2023;10:1183–97.
3. Chambers SA, et al. Rheumatology 2009;48:673–5.
4. Bruce IN, et al. Ann Rheum Dis. 2015;74:1706–13.
5. Fanouriakis A, et al. Ann Rheum Dis. 2024;83:15–29.
6. American College of Rheumatology. (2025). SLE Guideline Summary: 2025.
7. van Vollenhoven R, et al. Lupus Sci Med. 2022;9:e000634.

PSE-US-4198

Speakers

Presenter: Maria Dall’Era, MD
University of California, San Francisco
Division of Rheumatology
Professor of Medicine and Chief of the Division of Rheumatology
San Francisco, California

Presenter: Ashira Blazer, MD, MSCI
University of Maryland
Division of Rheumatology
Assistant Professor of Medicine
Baltimore, Maryland